Press Releases | DiaCarta, Inc.

DiaCarta Receives U.S. FDA Emergency Use Authorization for its Monkeypox Test Kit

by Claudia Li | Jan 12, 2023 | Press Releases

Press release DiaCarta Receives U.S. FDA Emergency Use Authorization for its Monkeypox Test Kit FollowFollow Pleasanton, California – Jan. 10, 2023 – DiaCarta, Ltd. (“DiaCarta”), a precision molecular diagnostics company, today announced that the U.S. Food and Drug...

DiaCarta Announces Successful Completion of Oncuria® Validation Study with Nonagen Bioscience

by Claudia Li | Jan 5, 2023 | Press Releases

Press release DiaCarta Announces Successful Completion of Oncuria® Validation Study with Nonagen Bioscience FollowFollow DiaCarta Starts to Receive Samples for Oncuria® Bladder Cancer Test at its CLIA Lab PLEASANTON, CA and LOS ANGELES, CA—January 5, 2023—DiaCarta,...

DiaCarta to Become a Publicly Listed Company Through Merger with HH&L Acquisition Co.

by Claudia Li | Oct 14, 2022 | Press Releases

Press release DiaCarta to Become a Publicly Listed Company Through Merger with HH&L Acquisition Co. FollowFollow PLEASANTON, Calif. & HONG KONG DiaCarta, Ltd. (“DiaCarta” or the “Company”), a precision molecular diagnostics company and developer of novel...

DiaCarta Receives CE-IVD Mark for Its SARS-CoV-2 Flu A/B Combo Test

by Claudia Li | Jul 20, 2022 | Press Releases

Press release Home ❯News & Events❯Press Releases❯ You are here ❯ Home ❯ Search ❯ RadTox ❯ DiaCarta Receives CE-IVD Mark for Its SARS-CoV-2 Flu A/B Combo Test FollowFollow PLEASANTON, Calif., July 20, 2022 DiaCarta Inc., a precision molecular diagnostics company and...

DiaCarta Expands Board Leadership with Industry Veteran

by Claudia Li | Apr 7, 2022 | Press Releases

Press release Home ❯News & Events❯Press Releases❯ You are here ❯ Home ❯ Search ❯ RadTox ❯ DiaCarta Expands Board Leadership with Industry Veteran FollowFollow Pleasanton, California, April 7, 2022. DiaCarta Inc., a precision molecular diagnostics company and leading...

DiaCarta Enters a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to Develop Cancer Tests based on its Novel XNA Technology

by Claudia Li | Jan 5, 2022 | Press Releases

Press release Home ❯News & Events❯Press Releases❯ You are here ❯ Home ❯ Blog ❯ DiaCarta Enters a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to Develop Cancer Tests based on its Novel XNA Technology FollowFollow...